698 related articles for article (PubMed ID: 30999929)
1. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
Huizinga TW; Batalov A; Stoilov R; Lloyd E; Wagner T; Saurigny D; Souberbielle B; Esfandiari E
Arthritis Res Ther; 2017 Mar; 19(1):53. PubMed ID: 28274253
[TBL] [Abstract][Full Text] [Related]
3. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
Behrens F; Tak PP; Østergaard M; Stoilov R; Wiland P; Huizinga TW; Berenfus VY; Vladeva S; Rech J; Rubbert-Roth A; Korkosz M; Rekalov D; Zupanets IA; Ejbjerg BJ; Geiseler J; Fresenius J; Korolkiewicz RP; Schottelius AJ; Burkhardt H
Ann Rheum Dis; 2015 Jun; 74(6):1058-64. PubMed ID: 24534756
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
5. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
[TBL] [Abstract][Full Text] [Related]
6. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC
Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
[TBL] [Abstract][Full Text] [Related]
7. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
[TBL] [Abstract][Full Text] [Related]
9. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Papp KA; Gooderham M; Jenkins R; Vender R; Szepietowski JC; Wagner T; Hunt B; Souberbielle B;
Br J Dermatol; 2019 Jun; 180(6):1352-1360. PubMed ID: 30207587
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
[TBL] [Abstract][Full Text] [Related]
13. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
[TBL] [Abstract][Full Text] [Related]
15. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
16. ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
Takeuchi T; Tanaka Y; Erdman J; Kaneko Y; Saito M; Higashitani C; Smulders R; Lademacher C
Arthritis Res Ther; 2020 Oct; 22(1):252. PubMed ID: 33087159
[TBL] [Abstract][Full Text] [Related]
17. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.
Genovese MC; Fleischmann R; Furst D; Janssen N; Carter J; Dasgupta B; Bryson J; Duncan B; Zhu W; Pitzalis C; Durez P; Kretsos K
Ann Rheum Dis; 2014 Sep; 73(9):1607-15. PubMed ID: 24641941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]